Molecular Products Group Announces Acquisition of the Henkel SODASORB®

Business

Louisville, CO, December 17, 2018 --(PR.com)-- Molecular Products Group, (“Molecular Products” or
the “Company”), a portfolio company of Arlington Capital Partners (“Arlington Capital”), today
announced the acquisition of the SODASORB® business from a fully owned subsidiary of Henkel AG &
Co. KGaA.

The SODASORB® product range includes carbon dioxide absorbents which have been trusted globally
for decades in the healthcare and safety industries. SODASORB® products help to safely and efficiently
remove carbon dioxide from anesthesia systems, saturation diving chambers, diving re-breathers, and
industrial safety equipment.

Troy Rhudy, CEO of the Molecular Products Group, said, “We're delighted to add the SODASORB®
product line to our existing product portfolio. The new capacity will enhance our ability to respond to
growing market demands and benefit our entire global customer base, while strengthening our position as
the global leader in carbon dioxide absorbent technologies.”

“The acquisition of SODASORB® further establishes Molecular Products in the strategically important
healthcare segment of the business, leveraging the Company's core chemical technologies and expanding
its capabilities,” said Peter Manos, Managing Partner of Arlington Capital Partners.

Malcom Little, a Principal of Arlington, added, “This acquisition demonstrates Molecular Products'
continued focus on highly strategic M&A to expand the Company's product offerings and enhance its
capabilities across all of its segments.”

About Molecular Products

Molecular Products is a Pure Air Technologies company and leading manufacturer of advanced
chemistry-based products serving the healthcare, defense and industrial markets. The Company
specializes in the manufacture and supply of chemical technologies for the treatment of breathable gases
and serves its global customer base out of its two primary manufacturing facilities in Louisville,
Colorado, USA and Harlow, Essex, UK. www.molecularproducts.com

Contact:
Louise Santos
lsantos@molprod.com
633 CTC Blvd.
Louisville, CO 80027
(303) 968-2604

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion
of committed capital via four investment funds. Arlington is focused on middle market investment

Page 1/3
PR.com Press Release Distribution Terms of Use
opportunities in growth industries, including: aerospace/defense, healthcare, government services and
technology, and business services and software. The firm's professionals and network have a unique
combination of operating and private equity experience that enable Arlington to be a value-added
investor. Arlington invests in companies in partnership with high quality management teams that are
motivated to establish and/or advance their Company's position as leading competitors in their field.
www.arlingtoncap.com

Contact:
Peter Manos & Malcolm Little
Arlington Capital Partners
5425 Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815
(202) 337-7500

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Molecular Products
Louise Santos
(303) 968-2604
Contact via Email
www.molecularproducts.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/772555

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use